MAGEA1抗体;MAGEA1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P12573(MAGEA1 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P12573(MAGEA1 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

The MAGE-A1 antibody targets the melanoma-associated antigen A1. a member of the MAGE (melanoma antigen gene) family. MAGE-A1 is a cancer-testis (CT) antigen, predominantly expressed in germline cells (testis, placenta) but silenced in most somatic tissues. Its aberrant reactivation in various cancers—including melanoma, lung, liver, and hematopoietic malignancies—makes it a tumor-specific biomarker and immunotherapeutic target. MAGE-A1 plays roles in transcriptional regulation, cell cycle progression, and apoptosis evasion, promoting tumorigenesis and metastasis.

Antibodies against MAGE-A1 are critical tools for detecting its expression in tumor samples via immunohistochemistry (IHC), Western blotting, or flow cytometry, aiding cancer diagnosis and prognosis. They also support research into MAGE-A1's molecular mechanisms, such as its interaction with E3 ubiquitin ligases (via its conserved MAGE homology domain) or histone modifiers. Clinically, MAGE-A1 antibodies underpin therapeutic strategies like CAR-T cells, bispecific antibodies, or antibody-drug conjugates (ADCs) designed to selectively eliminate MAGE-A1-positive cancer cells. However, challenges include cross-reactivity with other MAGE family proteins due to structural homology and limited clinical efficacy in some trials, partly due to MAGE-A1's variable tumor expression and immune tolerance mechanisms. Ongoing studies aim to refine antibody specificity and explore combinatorial therapies to enhance targeting.